Medicine & Health

A brain network first identified by WashU Medicine researchers, called SCAN, is shown in a new study to be the neurological basis for Parkinson’s disease. Patients receiving treatments targeted to this brain region, rather than to surrounding areas, experienced greater improvements in symptoms.

WashU psychology researcher Deanna Barch has won the Atkinson Prize in Psychological and Cognitive Sciences from the National Academy of Sciences, one of the most prestigious honors in psychology.

Jin-Moo Lee, MD, PhD, and Jeffrey R. Millman, PhD, at WashU Medicine were selected for the prestigious Falk Catalyst Awards, which supports bold early-stage research with the potential to transform patient care.

Thomas Kannampallil, chief data scientist and assistant dean for data science at WashU Medicine, and Laura Wiley, an associate professor of neurology at WashU Medicine, have been named 2025 American College of Medical Informatics fellows.

A multi-center study led by researchers at WashU Medicine and Michigan Medicine found that breathing problems during sleep are widespread among newborns with a severe form of spina bifida and could be a promising target for early interventions to improve the babies’ neurodevelopment.

Recent graduates, and undergraduate students who are close to graduating, can apply to be part of a two-year post-baccalaureate neuroscience program at WashU. Applications are due by March 9.

In a new study, WashU Medicine researchers show that vagus nerve stimulation provides substantial, long-lasting relief to some people with the most severe treatment-resistant depression.

A team of WashU researchers has integrated two novel vision-language models that create a potential AI assistant that may help people with cognitive decline cook meals and remain independent.

Researchers at Washington University in St. Louis have investigated how assemblies of molecules called microphases could be a useful target in developing treatments for neurodegenerative disorders.

In a new study, WashU Medicine researchers found that widely prescribed drugs such as Ritalin and Adderall don’t affect attention-controlling regions of the brain, as previously thought, but rather act on areas involved in wakefulness and reward.